ImmunoGen Inc. has inked yet another licensing deal with French pharmaceutical company Sanofi-Aventis.

Cambridge, Mass.-based ImmunoGen ((Nasdaq IMGN) announced on Wednesday that it had licensed non-exclusive rights to Sanofi-Aventis (NYSE SMY) for technology that works to make non-human antibodies appear human to the human immune system.

Sanofi-Aventis will use the technology to develop anti-cancer compounds included in an earlier collaborative agreement with ImmunoGen.

As part of the latest deal, ImmunoGen will earn a $1 million license fee, half of which is due when the contract is signed. The company is also eligible to receive up to $4.5 million in milestone payments, plus royalties.

In August, ImmunoGen announced it had extended its research collaboration with Sanofi-Aventis through Aug. 31, 2008. The companies began their first collaboration in July 2003.

ImmunoGen is developing anti-cancer treatments using tumor-targeting antibodies that deliver treatments directly to cancer cells.